Latest Contract research organizations Stories
Edgemont enhances its position as the leading M&A advisor to clinical research site companies NEW YORK, May 15, 2013 /PRNewswire/ -- Edgemont Capital Partners ("Edgemont"), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical Research ("Vince and Associates") in its sale to Altasciences Group. Vince and Associates manages complex early development clinical...
Patient experience and satisfaction identified as top priority for hospital leaders. Dallas, Texas (PRWEB) May 02, 2013 The Beryl Institute releases findings from its 2013 patient experience benchmarking study, revealing positive trends and continued focus by hospital leaders to define and support patient experience efforts. The bi-annual survey was the largest of its kind conducted to date, including 1,072 respondents from 672 unique organizations. Comparing the findings to the initial...
BOSTON, April 30, 2013 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL), a global clinical research organization, announced that today the Company acquired all of the outstanding equity securities of the HERON Group LTD ("HERON"), a life sciences consultancy which provides evidence-based commercialization services to support biopharmaceutical companies throughout the lifecycle of their products. HERON has expertise and methodologies spanning a wide range of services,...
RALEIGH, N.C., April 29, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the appointment of Thomas W. D'Alonzo to the company's Board of Directors. Mr. D'Alonzo previously served on the BDSI Board of Directors from August 2006 through June 2008. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) "We are very pleased to once again have Tom D'Alonzo as a member of our Board of Directors," said Dr. Frank E. O'Donnell, Jr., Executive...
Award highlights success of innovative strategic partnership at 22nd Annual Partnerships in Clinical Trials conference in Orlando, FL BOSTON, April 24, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced it has been named a recipient of the 2013 "Partnership Pioneers of the Year" award in recognition of its innovative strategic partnership with Pfizer and ICON. Given by the advisory board of the...
NEW YORK, April 23, 2013 /PRNewswire/ -- Intralinks® Holdings, Inc. (NYSE: IL), a leading, global SaaS provider of inter-enterprise content management and collaboration solutions, today announced the results of the 2013 Intralinks Global Investigator Site Survey. The survey looked at how clinical investigator sites currently perceive clinical web portals. The findings revealed that 80% of respondents agreed that a single web portal with one login to access studies across multiple...
Majority of biopharma executives believe Strategic Partnerships positively impact their engagement with CROs BOSTON, April 22, 2013 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today released a new research report called Strategic Partnerships 2013 at the 22(nd) Annual Partnerships in Clinical Trials Conference in Orlando, FL. The report is the first to explore the current outsourcing landscape and the value Strategic...
SHANGHAI, April 17, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2012 with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of...
PRINCETON, N.J., April 16, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of drug development services, today announced completion of the expansion of its central laboratory facility in Singapore to enhance the company's current service offerings and position it to meet current and future growth of drug development in the Asia Pacific region. The expansion is the latest in Covance's continued investment in Singapore, and an important element of the...
SHANGHAI, April 10, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2013 after the New York Stock Exchange closes on Monday, May 13, 2013 (which will be Tuesday morning, May 14, 2013 Shanghai time). The earnings release will be available on the investor...
